Potency and safety analysis of hemp-derived delta-9 products: The hemp vs. cannabis demarcation problem
 | |
| Clinical data | |
|---|---|
| Other names | ADK-910; Chlodantan; N-(2-Adamantyl)-N-(para-chlorobenzoyl)amine; 2-(para-Chlorobenzoylamino)adamantane |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C17H20ClNO |
| Molar mass | 289.80 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Chlodantane (developmental code name ADK-910) is a drug described as an adaptogen or actoprotector "of the estrogen activity type" that was developed in Russia and was never marketed.[1][2] It is an adamantane derivative and is closely related to bromantane (N-(2-adamantyl)-N-(para-bromophenyl)amine) and other adamantanes.[2][1] It has been said to improve physical performance.[2] However, only animal or cell culture research has been conducted and it has not been studied in humans.[2] The drug is described as having a broader spectrum of activity than bromantane.[1] It also has immunostimulant effects that are said to be more pronounced than those of bromantane.[1]
See also
References
- ^ a b c d Morozov IS, Ivanova IA, Lukicheva TA (2001). "Actoprotector and Adaptogen Properties of Adamantane Derivatives (A Review)". Pharmaceutical Chemistry Journal. 35 (5): 235–238. doi:10.1023/A:1011905302667.
- ^ a b c d Oliynyk S, Oh S (September 2012). "The pharmacology of actoprotectors: practical application for improvement of mental and physical performance". Biomolecules & Therapeutics. 20 (5): 446–456. doi:10.4062/biomolther.2012.20.5.446. PMC 3762282. PMID 24009833.
